Bing Yan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Insider Sell: Cytek Biosciences Inc s CTO Ming Yan Disposes of 20,000 Shares

Ming Yan, Chief Technology Officer of Cytek Biosciences Inc (NASDAQ:CTKB), sold 20,000 shares of the company on December 19, 2023, according to a recent SEC Filing.

Insider transactionNsider transactionsBing yanInsider sales

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongRhui zhouNew yorkUnited statesBing yanInnovent biologicsAdimab incyteEli lillyInnovent biologics incDrug administrationEuropean lung cancer congressIncyte corporationChina national medical products administrationMd anderson cancer centerAnheart therapeuticsDrug evaluation

AnHeart Therapeutics and Innovent Announce China s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation

AnHeart Therapeutics and Innovent Announce China s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Hong kongNew yorkUnited statesRhui zhouBing yanEli lillyAdimab incyteProduct serviceChina national medical products administrationIncyte corporationEuropean lung cancer congressMd anderson cancer centerDrug administrationInnovent biologics incHeart therapeuticsInnovent announce china

AnHeart Therapeutics and Innovent Announce China s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)

AnHeart Therapeutics and Innovent Announce China s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRhui zhouHong kongNew yorkBing yanCaicun zhouAdimab incyteCharlotte arnoldEli lillyIncyte corporationChina national medical products administrationDrug administrationInnovent biologics incEuropean lung cancer congressEuropean society of medical oncology congressMd anderson cancer center

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

New yorkUnited statesRhui zhouHong kongCaicun zhouEli lillyInnovent biologicsBing yanAdimab incyteIncyte corporationNational medical products administrationDrug administrationEuropean society of medical oncology congressMd anderson cancer centerEuropean lung cancer congressChina national medical products administration